DOCSLIB.ORG

BF3 Catalyzed Acetylation of Butylbenzene BF3 Katalysierte Acetylierung Von Butylbenzol Acetylation De Butylbenzene Catalysee Par BF3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BF3 Catalyzed Acetylation of Butylbenzene BF3 Katalysierte Acetylierung Von Butylbenzol Acetylation De Butylbenzene Catalysee Par BF3 Patentamt Europaisches ||| || 1 1| || || ||| || || || || || ||| || (19) J European Patent Office Office europeen des brevets (1 1 ) EP 0 488 638 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publicationation and mention (51 ) |nt. CI.6: C07C 45/46, C07C 49/76 of the grant of the patent: 02.01.1997 Bulletin 1997/01 (21) Application number: 91310859.3 (22) Dateof filing: 26.11.1991 (54) BF3 catalyzed acetylation of butylbenzene BF3 katalysierte Acetylierung von Butylbenzol Acetylation de butylbenzene catalysee par BF3 (84) Designated Contracting States: (74) Representative: De Minvielle-Devaux, Ian CH DE ES FR GB IT LI NL Benedict Peter et al CARPMAELS & RANSFORD (30) Priority: 27.11.1990 US 619157 43, Bloomsbury Square London WC1 A 2RA(GB) (43) Date of publication of application: 03.06.1992 Bulletin 1992/23 (56) References cited: EP-A-0 361 119 GB-A-2102 420 (73) Proprietor: HOECHST CELANESE US-A- 2 245 721 CORPORATION Somerville, N.J. 08876 (US) • World Patent Index database, Derwent Publ. London GB. Accession no. 73-433940, Derwent (72) Inventor: Lindley, Charlet R. week 7331 & SU-A-362845 (00.00.00) (Irkutsk Portland, Texas (US) Organic Chemistry Institute) CO CO CO CO CO CO Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in o a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. Q_ 99(1) European Patent Convention). LU Printed by Rank Xerox (UK) Business Services 2.13.10/3.4 EP 0 488 638 B1 Description 1 . Field of the Invention 5 This invention relates to an improved process for the acetylation of isobutylbenzene utilizing boron trifluoride as a catalyst and liquid sulfur dioxide as a solvent. 2. Description of Related Art 10 Aromatic ketones are valuable intermediates useful in the production of pharmaceutical compounds, cosmetics and in other applications. For example, U.S. Patent 4,607,125 discloses that hydroxy aromatic ketones, such as 4-hydroxyacetophenone, are useful in the production of N-acyl-p-aminophenol, better known as acetaminophen which has wide use as an analgesic. Acylation is accomplished by reacting phenol with an acylating agent such as acetic anhydride in the presence of a 15 Friedel-Crafts type catalyst such as aluminum chloride, hydrogen fluoride (HF) or boron trifluoride (BF3). HF is preferred because it also serves as a solvent medium for the reaction. U.K. Patent publication 21 02420A teaches the preparation of aromatic diaryl ketones by reacting a substituted ben- zene with an aromatic acyl compound in the presence of a mixture of a Lewis acid which may include BF3 and a strong acid which may include HF. The reaction medium may also include a polar solvent such as sulfur dioxide, tetramethyl- 20 ene sulfone, nitrobenzene and similar materials. U.S. Patent 4,454,350 discloses the preparation or p-haloacetophenones which are useful as intermediates in the preparation of pharmaceutical compounds and herbicides wherein starting materials such as fluorobenzene are reacted with an acylating agent such as acetic anhydride or acetyl chloride in a mixed system comprising HF as a sol- vent and BF3 as a catalyst. 25 European Patent Publication EP-199661-A teaches the acylation of biphenyl to produce 4-acetyl biphenyl or 4,4'- diacetyl biphenyl using an acetylating compound such as acetic anhydride and using HF, or a mixture of HF and CH2CI2 as solvents, and BF3 as the reaction catalyst. U.S. patent 4,474,990 discloses a similar process for the preparation of p-phenoxybenzoyl compounds, which are useful in the production of polyetherketone resins, by acylation of diphenyl ether using an acylating compound such as 30 acetic anhydride and HF as a catalyst and diluent. The reference indicates on the top of column 3 that the reaction media may also include an optional diluent such as alkanes, haloalkanes, sulfur dioxide and similar materials. Ibuprofen [2-(4'-isobutylphenyl)propionic acid] is a well-known nonsteroidal anti-inflammatory pharmaceutical which has been converted from ethical, i.e., prescription, to over-the-counter status. It is generally prepared by the cat- alytic acetylation of isobutyl benzene (IBB) with a suitable acetylation compound such as acetic anhydride to form 4- 35 isobutylacetophenone (IBAP). The reduction (catalytic hydrogenation) of IBAP leads to 1 -(4'-isobutylphenyl) ethanol (IBPE); carbonylation of IBPE yields Ibuprofen. The preparation of 4-isobutylacetophenone from isobutylbenzene is known in the art. For example, Braddely et al., Journal of the American Chemical Society, 4943-4945 (1956), discloses on p. 4945 the preparation of 4-isobutylace- tophenone by the Friedel-Crafts acetylation of isobutylbenzene with acetyl chloride using aluminum chloride as a cata- 40 lyst. In addition, Japanese Patent Publication no. 60 [1985]-1 88343 discloses the preparation of 4-isobutylacetophe- none by the acetylation of isobutylbenzene using acetyl fluoride as an acetylating agent, which is prepared by reacting acetic anhydride with HF as a catalyst, or a combination of HF and BF3 as catalysts. European Patent application 90305638.0 (EP-A-400,892) discloses a process for acetylating isobutylbenzene 45 using an appropriate acetylating agent such as acetic anhydride and in the presence of HF which serves as a catalyst and solvent. While all of the above and other acylation processes are effective to varying degrees, they suffer certain deficien- cies, particularly when scaled up for commercial production. For example, conventional Friedel Crafts catalysts such as aluminum chloride either can not be recycled or are recycled with difficulty from the reaction mass. In addition, HF is a so highly protic solvent and the separation of HF from an HF/BFs/aromatic ketone reaction product must be accomplished rapidly in order to avoid decomposition of the aromatic ketone reaction product. This would require the utilization of a reactor distillation column to effect this separation. Yet a third factor is the percent conversion of the aromatic starting material to the desired ketone and the selectivity of the process for producing the desired ketone as compared with its isomers. Conversion and selectivity are largely a function of the specific catalyst and the solvent employed in the proc- 55 ess. For example, in the commercial process for preparing 4-isobutylacetophenone from isobutylbenzene using acetic anhydride as an acetylating agent and HF as a catalyst, the reaction generally proceeds with less than 90% conversion of the isobutylbenzene starting material and less than 85% selectivity toward production of the desired 4-isomer vs. other isomers such as the 3-isomer or 3,4-isomer combination. Such drawbacks result in production inefficiencies due to the requirement for additional separation and/or purif ica- 2 EP 0 488 638 B1 tion steps in the production process, as well as equipment for accomplishing these steps, and lower yields of the desired product. Acylation of aromatic compounds using an aluminum halide catalyst and a solvent medium other than HF have been described in the prior art. For example, U.S. Patent 2,245,721 discloses the acylation of aromatic compounds by 5 reaction with carboxylic acid halides or anhydrides in the presence of an aluminum halide catalyst and liquid sulfur diox- ide as a solvent. Although the patent describes numerous advantages which arise as the result of using sulfur dioxide in the process, the yield of reaction product is extremely low, e.g, a 45% yield of acetophenone from benzene and acetyl chloride using an aluminum chloride catalyst as indicated in Example 4 of the patent. Also, as pointed out above, the aluminum chloride catalyst cannot be recycled for further use as is desirable in a commercial scale process. 10 Also of interest is JP-A-60-1 88343, which discloses the production of an aromatic ketone by the reaction of an aro- matic compound, e.g. toluene, naphthalene or phenol, with an acyl fluoride prepared by reacting a slight excess of an acid anhydride, e.g. acetic anhydride or propionic anhydride, with hydrogen fluoride and isolating the acyl fluoride from free acid. The reaction of the aromatic compound and the acyl fluoride is carried out in the presence of hydrogen fluo- ride alone or optionally mixed with boron trifluoride. 15 It is an object of this invention to provide an efficient and economical process for preparing 4-isobutylacetophe- none. Another object of this invention is to provide a process for acylating isobutylbenzene without the need to use highly protonic solvents. Another object is to provide a process for preparing 4-isobutylacetophenone wherein a high conversion of the iso- 20 butylbenzene starting material is realised. Yet another object is to provide an acetylation process which is highly selective towards the production of 4-isobuty- lacetophenone in contrast to its related isomers. SUMMARY OF THE INVENTION 25 The present invention provides a process for preparing isobutylacetophenone from isobutylbenzene, said isobuty- lacetophenone containing at least 98 percent selectivity of 4-isobutylacetophenone isomer, and said process compris- ing acetylating isobutylbenzene with an acetylating agent selected from the group consisting of acetic acid, acetic anhydride, acetyl fluoride, acetyl chloride and acetyl bromide, in the presence of a solvent comprising anhydrous sulfur 30 dioxide and catalytic quantities of BF3, said acetylation being accomplished at a temperature that is initially maintained at no more than -20°C for at least one minute and may then be adjusted (and preferably is increased) to no more than 50°C until said acetylation is completed. The acylation proceeds in accordance with the equation I: wherein Y is -OH, 0 50 II -C-CH3, 55 -F, -CI or -Br.
Load more

Recommended publications
  • "Fluorine Compounds, Organic," In: Ullmann's Encyclopedia Of
    Article No : a11_349 Fluorine Compounds, Organic GU¨ NTER SIEGEMUND, Hoechst Aktiengesellschaft, Frankfurt, Federal Republic of Germany WERNER SCHWERTFEGER, Hoechst Aktiengesellschaft, Frankfurt, Federal Republic of Germany ANDREW FEIRING, E. I. DuPont de Nemours & Co., Wilmington, Delaware, United States BRUCE SMART, E. I. DuPont de Nemours & Co., Wilmington, Delaware, United States FRED BEHR, Minnesota Mining and Manufacturing Company, St. Paul, Minnesota, United States HERWARD VOGEL, Minnesota Mining and Manufacturing Company, St. Paul, Minnesota, United States BLAINE MCKUSICK, E. I. DuPont de Nemours & Co., Wilmington, Delaware, United States 1. Introduction....................... 444 8. Fluorinated Carboxylic Acids and 2. Production Processes ................ 445 Fluorinated Alkanesulfonic Acids ...... 470 2.1. Substitution of Hydrogen............. 445 8.1. Fluorinated Carboxylic Acids ......... 470 2.2. Halogen – Fluorine Exchange ......... 446 8.1.1. Fluorinated Acetic Acids .............. 470 2.3. Synthesis from Fluorinated Synthons ... 447 8.1.2. Long-Chain Perfluorocarboxylic Acids .... 470 2.4. Addition of Hydrogen Fluoride to 8.1.3. Fluorinated Dicarboxylic Acids ......... 472 Unsaturated Bonds ................. 447 8.1.4. Tetrafluoroethylene – Perfluorovinyl Ether 2.5. Miscellaneous Methods .............. 447 Copolymers with Carboxylic Acid Groups . 472 2.6. Purification and Analysis ............. 447 8.2. Fluorinated Alkanesulfonic Acids ...... 472 3. Fluorinated Alkanes................. 448 8.2.1. Perfluoroalkanesulfonic Acids
    [Show full text]
  • Used at Rocky Flats
    . TASK 1 REPORT (Rl) IDENTIFICATION OF CHEMICALS AND RADIONUCLIDES USED AT ROCKY FLATS I PROJECT BACKGROUND ChemRisk is conducting a Rocky Flats Toxicologic Review and Dose Reconstruction study for The Colorado Department of Health. The two year study will be completed by the fall of 1992. The ChemRisk study is composed of twelve tasks that represent the first phase of an independent investigation of off-site health risks associated with the operation of the Rocky Flats nuclear weapons plant northwest of Denver. The first eight tasks address the collection of historic information on operations and releases and a detailed dose reconstruction analysis. Tasks 9 through 12 address the compilation of information and communication of the results of the study. Task 1 will involve the creation of an inventory of chemicals and radionuclides that have been present at Rocky Flats. Using this inventory, chemicals and radionuclides of concern will be selected under Task 2, based on such factors as the relative toxicity of the materials, quantities used, how the materials might have been released into the environment, and the likelihood for transport of the materials off-site. An historical activities profile of the plant will be constructed under Task 3. Tasks 4, 5, and 6 will address the identification of where in the facility activities took place, how much of the materials of concern were released to the environment, and where these materials went after the releases. Task 7 addresses historic land-use in the vicinity of the plant and the location of off-site populations potentially affected by releases from Rocky Flats.
    [Show full text]
  • Rpt POL-TOXIC AIR POLLUTANTS 98 BY
    SWCAA TOXIC AIR POLLUTANTS '98 by CAS ASIL TAP SQER CAS No HAP POLLUTANT NAME HAP CAT 24hr ug/m3 Ann ug/m3 Class lbs/yr lbs/hr none17 BN 1750 0.20 ALUMINUM compounds none0.00023 AY None None ARSENIC compounds (E649418) ARSENIC COMPOUNDS none0.12 AY 20 None BENZENE, TOLUENE, ETHYLBENZENE, XYLENES BENZENE none0.12 AY 20 None BTEX BENZENE none0.000083 AY None None CHROMIUM (VI) compounds CHROMIUM COMPOUN none0.000083 AY None None CHROMIUM compounds (E649962) CHROMIUM COMPOUN none0.0016 AY 0.5 None COKE OVEN COMPOUNDS (E649830) - CAA 112B COKE OVEN EMISSIONS none3.3 BN 175 0.02 COPPER compounds none0.67 BN 175 0.02 COTTON DUST (raw) none17 BY 1,750 0.20 CYANIDE compounds CYANIDE COMPOUNDS none33 BN 5,250 0.60 FIBROUS GLASS DUST none33 BY 5,250 0.60 FINE MINERAL FIBERS FINE MINERAL FIBERS none8.3 BN 175 0.20 FLUORIDES, as F, containing fluoride, NOS none0.00000003 AY None None FURANS, NITRO- DIOXINS/FURANS none5900 BY 43,748 5.0 HEXANE, other isomers none3.3 BN 175 0.02 IRON SALTS, soluble as Fe none00 AN None None ISOPROPYL OILS none0.5 AY None None LEAD compounds (E650002) LEAD COMPOUNDS none0.4 BY 175 0.02 MANGANESE compounds (E650010) MANGANESE COMPOU none0.33 BY 175 0.02 MERCURY compounds (E650028) MERCURY COMPOUND none33 BY 5,250 0.60 MINERAL FIBERS ((fine), incl glass, glass wool, rock wool, slag w FINE MINERAL FIBERS none0.0021 AY 0.5 None NICKEL 59 (NY059280) NICKEL COMPOUNDS none0.0021 AY 0.5 None NICKEL compounds (E650036) NICKEL COMPOUNDS none0.00000003 AY None None NITROFURANS (nitrofurans furazolidone) DIOXINS/FURANS none0.0013
    [Show full text]
  • Modelling and Synthesis of Pharmaceutical Processes: Moving from Batch to Continuous
    Downloaded from orbit.dtu.dk on: Dec 18, 2017 Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Papadakis, Emmanouil; Gani, Rafiqul; Woodley, John Publication date: 2016 Document Version Peer reviewed version Link back to DTU Orbit Citation (APA): Papadakis, E., Gani, R., & Woodley, J. (2016). Modelling and synthesis of pharmaceutical processes: moving from batch to continuous. Kgs. Lyngby: Technical University of Denmark (DTU). General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. 2016 Modelling and synthesis of pharmaceutical processes: moving from batch to continuous to batch from moving pharmaceutical processes: of Modelling and synthesis Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Emmanouil Papadakis PhD Thesis September 2016 Department of Chemical and Biochemical Engineering Technical University of Denmark Søltofts Plads, Building 229 2800 Kgs. Lyngby Emmanouil Papadakis Denmark Phone: +45 45 25 28 00 Web: www.kt.dtu.dk/ Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Doctor of Philosophy Thesis Emmanouil Papadakis KT-Consortium Department of Chemical and Biochemical Engineering Technical University of Denmark Kgs.
    [Show full text]
  • United States Patent Office Patented Sept
    2,717,871 United States Patent Office Patented Sept. 13, 1955 2 pure form by a suitable procedure. Numerous other 2,717,871 derivatives can be made from these initial derivatives. ELECTROCHEMICAL PRODUCTION OF FLUCR0. Unsaturated acids as well as saturated acids can be used CARBON ACID FLUORE)E DERVATIVES as starting compounds and saturation is produced by Harold M. Scholberg, St. Paul, Min, and fugh G. 5 fluorine addition during the electrochemical fluorination. Bryce, Hudson, Wis., assignors to Minnesota Mining The electrochemical process is not limited to the pro & Manufacturing Company, St. Paul, Minn., a corpo" duction of monocarboxylate compounds. The hydrocar ration of Delaware bon polycarboxylic acids (and their anhydrides) can be fluorinated to produce the corresponding fluorocarbon acid No Drawing. Application February 1, 1952, fluorides, the hydrogen atoms and the hydroxyl groups Serial No. 269,584 of the starting acid being replaced by fluorine atoms. The fluorocarbon acid fluorides can be generically represented 3 Claims. (Cl. 204-59) by the formula: This invention relates to our discovery of a new and Rf (COF)m useful process of making saturated fluorocarbon acid fluo where n is an integer having a value of 1 for monocar rides, which are converted to derivatives thereof and re boxylic acid fluorides, a value of 2 for dicarboxylic acid covered as such. It is an improvement upon the electro fluorides, etc. chemical procedures described in the U.S. patents of J. H. The process as heretofore described and used, outlined Simons, No. 2,519,983 (August 22, 1950), and A. R. above, has the economic disadvantage of producing rela Diesslin, E.
    [Show full text]
  • 6 CCR 1010-6 [Editor’S Notes Follow the Text of the Rules at the End of This CCR Document.]
    DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT Division of Environmental Health and Sustainability RULES AND REGULATIONS GOVERNING SCHOOLS IN THE STATE OF COLORADO 6 CCR 1010-6 [Editor’s Notes follow the text of the rules at the end of this CCR Document.] _________________________________________________________________________ 6.1 Authority This regulation is adopted pursuant to the authority in Sections 25-1-108(1)(c)(I), 25-1.5-101(1)(a),(h), (k), and (l), and 25-1.5-102(1)(a) and (d), Colorado Revised Statute (C.R.S.), and is consistent with the requirements of the State Administrative Procedures Act, Section 24-4-101, et seq., C.R.S. 6.2 Scope and Purpose A. This regulation establishes provisions governing: 1. Minimum sanitation requirements for the operation and maintenance of schools; 2. Minimum standards for exposure to toxic materials and environmental conditions in order to safeguard the health of the school occupants and the general public; and 3. Investigation, control, abatement and elimination of sources causing epidemic and communicable diseases affecting school occupants and public health. B. This regulation does not apply to: 1. Structures or facilities used by a religious, fraternal, political or social organization exclusively for worship, religious instructional or entertainment purposes pertaining to that organization; 2. Health facilities licensed by the Colorado Department of Public Health and Environment under provisions of Section 25-3-101, C.R.S.; and 3. Child care facilities licensed by the Colorado Department of Human Services under provisions of Sections 26-6-102(1.5), (2.5)(a), (5), (5.1), (8), (9), (10)(a), C.R.S.
    [Show full text]
  • Ep 0250206 A2
    Europaisches Patentamt 0 250 206 J European Patent Office © Publication number: A2 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 87305325.0 © int. CIA C07C 102/00 , C07C 103/38 , C07C 45/46 , C07C 131/00 @ Date of filing: 16.06.87 © Priority: 17.06.86 US 875142 © Applicant: CELANESE CORPORATION 1211 Avenue of the Americas @ Date of publication of application: New York New York 10036(US) 23.12.87 Bulletin 87/52 @ Inventor: Davenport, Kenneth G. © Designated Contracting States: 3126 Crestwater AT BE CH DE ES FR GB GR IT LI LU NL SE Corpus Christi Texas, 7841 5(US) Inventor: Hilton, Charles B. 1305 Cliffwood Road Euless Texas, 76040(US) © Representative: De Minvielle-Oevaux, Ian Benedict Peter et al CARPMAELS & RANSFORD 43, Bloomsbury Square London WC1A 2RA(GB) © Process for producing N,O-diacetyl-6-amino-2-naphthol. © N,O-diacetyl-6-amino-2-naphthol is produced by subjecting 2-naphthyl acetate to a Fries rearrangement or 2- naphthol and an acetylating agent to a Friedel-Crafts acetylation to form 6-hydroxy-2-acetonaphthone which is then reacted as is or as its acetate ester with hydroxylamine or a hydroxylamine salt to form 6-hydroxy-2- acetonaphthone oxime. The oxime is then subjected to a Beckmann rearrangement and accompanying acetylation with acetic anhydride to form the N,O-diacetyl-6-amino-2-naphthol. < CO o w © CM 0_ LU Xerox Copy Centre 0 250 206 PROCESS FOR PRODUCING N,O-DIACETYL-6-AMINO-2-NAPHTHOL This invention relates to an integrated process for the production of N,O-diacetyl-6-amino-2-naphthol (NODAN), from 2-naphthyl acetate, or 2-naphthol and an acetylating agent as the starting material.
    [Show full text]
  • Modelling and Synthesis of Pharmaceutical Processes: Moving from Batch to Continuous
    Downloaded from orbit.dtu.dk on: Dec 23, 2016 Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Papadakis, Emmanouil; Gani, Rafiqul; Woodley, John Publication date: 2016 Document Version Peer reviewed version Link to publication Citation (APA): Papadakis, E., Gani, R., & Woodley, J. (2016). Modelling and synthesis of pharmaceutical processes: moving from batch to continuous. Kgs. Lyngby: Technical University of Denmark. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. 2016 Modelling and synthesis of pharmaceutical processes: moving from batch to continuous to batch from moving pharmaceutical processes: of Modelling and synthesis Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Emmanouil Papadakis PhD Thesis September 2016 Department of Chemical and Biochemical Engineering Technical University of Denmark Søltofts Plads, Building 229 2800 Kgs. Lyngby Emmanouil Papadakis Denmark Phone: +45 45 25 28 00 Web: www.kt.dtu.dk/ Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Doctor of Philosophy Thesis Emmanouil Papadakis KT-Consortium Department of Chemical and Biochemical Engineering Technical University of Denmark Kgs.
    [Show full text]
  • Acetic Acid Toxic
    Chemical Waste Name or Mixtures: Listed Characteristic Additional Info Disposal Notes (-)-B- bromodiisopropinocampheyl (-)-DIP-Bromide Non Hazardous None liquid: sanitary sewer/ solid: trash borane (-)-B- chlorodiisopropinocampheylb (-)-DIP-Chloride Non Hazardous None liquid: sanitary sewer/ solid: trash orane [(-)-2-(2,4,55,7-tetranitro-9- fluorenyodeneaminooxy)pro (-)-TAPA Non Hazardous None liquid: sanitary sewer/ solid: trash pionic acid] (+)-B- bromodiisopropinocampheyl (+)-DIP-Bromide Non Hazardous None liquid: sanitary sewer/ solid: trash borane (+)-B- chlorodiisopropinocampheylb (+)-DIP-Chloride Non Hazardous None liquid: sanitary sewer/ solid: trash orane [(+)-2-(2,4,55,7-tetranitro-9- fluorenylideneaminooxy)prop (+)-TAPA Non Hazardous None liquid: sanitary sewer/ solid: trash ionic acid] (2,4,5-Trichlorophenoxy) Acetic Acid Toxic None EHS NA (2,4-Dichlorophenoxy) Acetic Acid Toxic None EHS NA trans-8,trans-10-dodecadien- (E,E)-8,10-DDDA Non Hazardous None liquid: sanitary sewer/ solid: trash 1-ol trans-8,trans-10-dodecadien- (E,E)-8,10-DDDOL Non Hazardous None liquid: sanitary sewer/ solid: trash 1-yl acetate trans-7,cis-9-dodecadien-yl (E,Z)-7,9-DDDA Non Hazardous None liquid: sanitary sewer/ solid: trash acetate (Hydroxypropyl)methyl Cellulose Non Hazardous None liquid: sanitary sewer/ solid: trash NA ammonium phosphate (NH4)2HPO4 Non Hazardous None liquid: sanitary sewer/ solid: trash (dibasic) (NH4)2SO4 Non Hazardous None liquid: sanitary sewer/ solid: trash ammonium sulfate ammonium phosphate (NH4)3PO4 Non Hazardous None
    [Show full text]
  • Process for Producing Acetyl-Substituted Aromatic
    turopaisches Patentamt European Patent Office © Publication number: 0 21 5 351 Office europeen des brevets A2 <2> EUROPEAN PATENT APPLICATION © Application number: 86111905.5 © int. CI.4: C07C 45/46 C07C , 49/76 , C07C 49/788 C07C 49/825 ®r\ Daten of 28'08-86„ , , f,l,n9: C07C 49/83 , C07C 49/84 © Priority: 31.08.85 JP 191521/85 © Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC. © Date of publication of application: 5-2, Marunouchi 2-chome Chiyoda-Ku 25.03.87 Bulletin 87/13 Tokyo(JP) © Designated Contracting States: @ Inventor: Fujiyama, Susumu DE FR GB IT NL 522-65, Kamitomii Kurashiki-shi(JP) Inventor: Matsumoto, Shunichi 1168-3, Tanoue Kurashiki-shi(JP) Inventor: Yanagawa, Tatsuhiko 1987, Nakashima Kurashiki-shi(JP) © Representative: Patentanwalte Griinecker, Kinkeldey, Stockmair & Partner Maximilianstrasse 58 D-8000 Munchen 22{DE) Process for producing acetyi-substituted aromatic compound. v=y This invention provides a process for producing an acetyi-substituted aromatic compound by making an aromatic compound react with acetyl fluoride in the presence of substantially anhydrous hydrogen fluoride as a catalyst. M It has been already known to acylate- an ar- ^omatic compound with an acid fluoride in the pres- ence of boron fluoride or hydrogen fluoride and O boron fluoride as a catalyst. It has been found that, *^in a reaction of an aromatic compound with acetyl fjfluoride, even when hydrogen fluoride alone is used ■as a catalyst, the intended acetyi-substituted ar- ^omatic compound can be obtained in excellent yield 5 and further the complex compound formed can be ^decomposed without difficulty and the hydrogen flu- yoride catalyst can be easily recovered.
    [Show full text]
  • Modelling and Synthesis of Pharmaceutical Processes: Moving from Batch to Continuous
    Downloaded from orbit.dtu.dk on: Oct 10, 2021 Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Papadakis, Emmanouil Publication date: 2016 Document Version Peer reviewed version Link back to DTU Orbit Citation (APA): Papadakis, E. (2016). Modelling and synthesis of pharmaceutical processes: moving from batch to continuous. Technical University of Denmark. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. 2016 Modelling and synthesis of pharmaceutical processes: moving from batch to continuous to batch from moving pharmaceutical processes: of Modelling and synthesis Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Emmanouil Papadakis PhD Thesis September 2016 Department of Chemical and Biochemical Engineering Technical University of Denmark Søltofts Plads, Building 229 2800 Kgs. Lyngby Emmanouil Papadakis Denmark Phone: +45 45 25 28 00 Web: www.kt.dtu.dk/ Modelling and synthesis of pharmaceutical processes: moving from batch to continuous Doctor of Philosophy Thesis Emmanouil Papadakis KT-Consortium Department of Chemical and Biochemical Engineering Technical University of Denmark Kgs.
    [Show full text]
  • (Ug/M3) Long-Term ESL (Ppb) Date Derived Status Short
    Long-term Short-term ESL Short-term ESL Long-term ESL ESL Substance CASNo. (ug/m3) (ppb) (ug/m3) (ppb) Date Derived Status Short-term ESL Basis Long-term ESL Basis ((2-(Dimethylamino)ethyl)methylamino)-ethanol, 2- 2212-32-0 50 -- 5 -- 8/19/2010 Interim Health Health ([dimethylamino] methyl) phenol 25338-55-0 190 -- 19 -- 4/19/2004 Interim Health Health (2-nitrobutyl) morpholine, 4- 2224-44-4 200 -- 20 -- 4/14/2004 Interim Health Health (3-dimethylamino) propylhexahydro-s-triazine, 1,3,5-tris 15875-13-5 50 (PM10) -- 5 (PM10) -- 3/25/2004 Interim Health Health (4-Methylphenylimino)diethanol, 2,2'- 3077-12-1 50 (PM10) -- 5 (PM10) -- 10/28/2010 Interim Health Health (dimethylamino)-3,5-xylyl methylcarbamate, 4- 315-18-4 5 -- 0.5 -- 10/1/2003 Interim Health Health (dimethylbutyl, 1,3-) -n'-phenylenediamine, n- 793-24-8 10 -- 1 -- 3/30/2001 Interim Health Health (ethyl-2-nitrotrimethylene, 2-) dimorpholine, 4,4- 1854-23-5 200 -- 20 -- 11/10/2000 Interim Health Health (hydroxyethyl, 2-)-3-methoxy propanamide, n- (MHPA) 35544-45-7 700 -- 70 -- 2/16/2001 Interim Health Health (imidazole, 1H-) -1-ethanamine, 4,5-dihydro-, 2- nornaphthenyl derives 68478-61-5 50 -- 5 -- 5/10/2004 Interim Health Health (imidazolium, 1H), 1-ethyl-4,5-dihydro-3-(2- hydroxyethyl)-2-(8-heptadecnyl)-ethyl sulfate Not assigned 150 -- 15 -- 6/16/1998 Interim Health Health (mercaptopropyl, 3-) triethoxysilane, gamma- (also called EMS) 14814-09-6 50 -- 5 -- 2/17/2004 Interim Health Health (mercaptopropyl, 3-) trimethoxysilane, gamma- (also called MMS) 4420-74-0 50 -- 5 --
    [Show full text]